Share This Activity
From:
To:
Subject: I'd like to recommend this activity on www.PracticePointCME.com
Message:

Hepatitis

Emerging Hepatitis C Treatment Strategies For Difficult‐to‐Cure Patients
A Certified CME/CE Symposium Archive

The availability of newer direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms has transformed HCV management. Many of these newer regimens are administered as a once-daily single tablet and provide high cure rates across multiple genotypes. Despite these advances, some patients remain more difficult to cure, and management guidance from clinical trial data may be limited.

This enduring activity will address emerging HCV treatment strategies for patients with liver/renal comorbidity and the role and the role of resistance testing in regimen selection.
This activity has been approved for 1.5 credits/contact hours. Credit/contact hours may be claimed for viewing all links and after completion of the brief Post-Test/Evaluation.




Mark S. Sulkowski, MD Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Johns Hopkins University
School of Medicine
Tram T. Tran, MD Tram T. Tran, MD
Medical Director, Liver Transplant
Professor of Medicine
Cedars Sinai Medical Center
Paul Kwo, MD Paul Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University
Fred Poordad, MD Fred Poordad, MD
Professor of Medicine
University of Texas
Health Science Center
at San Antonio
Chief, Hepatology
VP, Academic and Clinical Affairs
Texas Liver Institute

Please review the below required information (use scroll bar on the right)
and then click the
"Watch Video Presentation"
button to access this activity

INTRODUCTION

The availability of newer direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms has transformed HCV management. Many of these newer regimens are administered as a once-daily single tablet and provide high cure rates across multiple genotypes. Despite these advances, some patients remain more difficult to cure, and management guidance from clinical trial data may be limited. This interactive, case-based activity will address emerging HCV treatment strategies for patients with liver/renal comorbidity and the role and the role of resistance testing in regimen selection.

Release Date: November 12, 2016
Expiration Date: October 31, 2017

TARGET AUDIENCE

This activity is intended for physicians, physician assistants, registered nurses, and nurse practitioners who care for persons with hepatitis C.

LEARNING OBJECTIVES

Upon completion of this enduring material, participants should be able to:

    METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

    • There are no fees for participating in and receiving credit for this activity.
    • Review the activity objectives and CME/CE information.
    • Review all modules associated with this course
    • Successfully complete the post-test ( accuracy)
    • Complete the CME/CE evaluation
    • The estimated time to complete this activity is hour.
    • Upon successful completion of the initial evaluation, your CME/CNE certificate will be available to print for your records. CPE credit will be submitted to the University of Florida and posted to CPE Monitor

    JOINT PROVIDERSHIP

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, the University of Nebraska Medical Center College of Nursing Continuing Nursing Education, the University of Florida College of Pharmacy, and Practice Point Communications.

    ACCREDITATION STATEMENTS

    PHYSICIANS/PHYSICIAN ASSISTANTS
    University of NebraskaThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Practice Point Communications.

    The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians. The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NURSES/NURSE PRACTITIONERS
    The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is provided for 1.5 contact hours under ANCC criteria.

    PHARMACISTS
    UFThis knowledge based activity is accredited for 1.5 hours of continuing pharmacy education (CPE) credit. The University of Florida College of Pharmacy will report all credit to CPE Monitor within 60 working days after receiving evidence of successful completion of the course. Successful completion includes achieving a score of at least on the test and completed evaluation.

    ACPEThe University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (UAN #0012-9999-16-474-H01-P).


    Participation in the entire knowledge based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.

    RESOLUTION OF CONFLICT OF INTEREST

    In accordance with the ACCME Standards for Commercial Support of CME, the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education, the University of Florida College of Pharmacy, and Practice Point Communications will implement mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

    DISCLOSURE

    It is the policy of the accreditors named above to ensure balance, independence, objectivity, and scientific rigor in all their educational activities. All faculty participating in this activity are expected to disclose to the audience relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. Faculty must also disclose any planned discussions of off-label/unapproved uses of drugs or devices during their presentation(s). Please consult the full prescribing information of any medication mentioned in these educational activities before its use.

    All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education, and the University of Florida College of Pharmacy.

    The following indicates the disclosure declaration information and the nature of those commercial relationships.

    DISCLOSURES

    The speakers and planning committee members listed below have stated they have no significant relationships to disclose.
    Heidi Keeler, PhD, RN
    Lois Colburn
    Chris Fleming
    Jill Valone

    FACULTY DISCLOSURES

    The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias:

    Paul Kwo, MD
    Employment: None
    Industry funded researcher/investigator: AbbVie, BMS, Gilead Sciences, Janssen, Merck
    Consultant: None
    Speakers Bureau, Faculty, Peer Reviewer: None
    Advisory Committee/Board: AbbVie, BMS, Gilead Sciences, Janssen, Merck
    Stock/Ownership: None
    Patent Holder: None
    Other: None

    Fred Poordad, MD
    Employment: None
    Industry funded researcher/investigator: None
    Consultant: None
    Speakers Bureau, Faculty, Peer Reviewer: AbbVie, Gilead Sciences, BMS, Merck
    Advisory Committee/Board: AbbVie, Gilead Sciences, BMS, Merck
    Stock/Ownership: None
    Patent Holder: None
    Other: None

    Mark S. Sulkowski, MD
    Employment: None
    Industry funded researcher/investigator: AbbVie, BMS, Gilead Sciences, Janssen, Merck
    Consultant: AbbVie, CoCrystal, Cotravir, Gilead Sciences, Janssen, Merck, Trek
    Speaker Bureau, Faculty, Peer Reviewer: None
    Advisory Committee/Board: None
    Stock/Ownership: None
    Patent Holder: None
    Other: None

    Tram T. Tran, MD
    Employment: None
    Industry funded researcher/investigator: Gilead Sciences
    Consultant: Gilead Sciences
    Speaker Bureau, Faculty, Peer Reviewer: Gilead Sciences
    Advisory Committee/Board: Gilead Sciences
    Stock/Ownership: None
    Patent Holder: None
    Other: None

    DISCLAIMER

    The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education, University of Florida College of Pharmacy, and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education, the University of Florida College of Pharmacy, Practice Point Communications, and Gilead Sciences Medical Affairs assume no liability for the information herein. Accredited status as a continuing nursing education provider refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center Commission on Accreditation endorsement of any commercial supporters.

    PRIVACY POLICY

    The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education, the University of Florida College of Pharmacy, and Practice Point Communications protects the privacy of personal and other information regarding participants and educational collaborators. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education, University of Florida College of Pharmacy, and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.

    The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education, the University of Florida College of Pharmacy, and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

    COPYRIGHT INFORMATION

    Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:

    The Materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

    Materials may not be published, uploaded, posted, transmitted (other than as set forth herin), without prior written permission.

    OPINIONS AND OFF-LABEL DISCUSSIONS

    In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

    HARDWARE/SOFTWARE REQUIREMENTS

    Computer:
    • Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
    • Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution
    • Network: An Internet connection with 1Mbps available download & 256kbps bandwidth
    Software/Browser:
    • Windows XP or above running Internet Explorer 7 (service pack 2) or above.
    • MAC OSX 10.5 (Leopard) or above running Safari 5.1 or above, or any version of Chrome, Firefox or Opera published in the last two years.
    • A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above
    Mobile Device:
    • Any Apple iPad or iPad Mini running IOS 5 or above.
    • Most high-performance Android tablets such as the Kindle Fire or Samsung Galaxy S
    This presentation should be viewed with Microsoft PowerPoint. If Microsoft PowerPoint is not used to view the slides, data from charts may be incorrect or incomplete.

    COMMERCIAL SUPPORT ACKNOWLEDGMENT

    Supported by an independent educational grant from Merck & Co.

    Presented for attendees at the 67th AASLD Annual Meeting (or The Liver Meeting®). This activity is jointly sponsored by the University of Nebraska Medical Center and Practice Point Communications and supported by Merck & Co. This is not an official function/event of the American Association for the Study of Liver Diseases.


    20
    Supported by an independent educational grant from Merck & Co.
    970
    720
    October 31, 2017
    Mini Module
    6126
    AASLD16_WebBanner2-1158px.gif

    World Hep Day

    Upcoming Live Activities

    No upcoming live activities
    Copyright 2017 by Practice Point Communications